Results 191 to 200 of about 30,982 (215)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong

Respirology, 2022
BACKGROUND AND OBJECTIVE: Few head-to-head evaluations of immune responses to different vaccines have been reported. METHODS: Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or ...
Malik Peiris, Gaya K. Amarasinghe, Chris Ka Pun Mok   +2 more
exaly   +2 more sources

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon [PDF]

Vaccine, 2021
Facing new COVID-19 waves, the effectiveness of BBIBP-CorV has been noted to be low in countries whose populations were already administered two doses of the vaccine.
Abdul Rahman Bizri, Rima Moghnieh, Mohamed Sayegh   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Decreased Infectivity Following BNT162b2 Vaccination

SSRN Electronic Journal, 2021
Background: BNT162b2 was shown to be 92% effective in preventing COVID-19. Prioritizing vaccine rollout, and achievement of herd immunity depend on SARS-CoV-2 transmission reduction. The vaccine’s effect on infectivity is thus a critical priority. Methods: In a cohort of all 9650 HCW of a large single tertiary medical center, we calculated the ...
Gili Regev-Yochay, Sharon Amit, Moriah Bergwerk, Marc Lipsitch, Eyal Leshem, Rebecca Kahn, Yaniv Lustig, Carmit Cohen, Ram Doolman, Arnona Ziv, Ilya Novikov, Carmit Rubin, Irena Gimpelevich, Amit Huppert, Galia Rahav, Arnon Afek, Yitshak Kreiss   +16 more
openaire   +1 more source

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents

Pediatrics, 2023
OBJECTIVES We assessed BNT162b2 vaccine effectiveness (VE) against mild to moderate and severe coronavirus disease 2019 (COVID-19) in children and adolescents through the Omicron BA.4/BA.5 period. METHODS Using VISION Network records from April 2021
Nicola P, Klein, Maria, Demarco, Katherine E, Fleming-Dutra, Melissa S, Stockwell, Anupam B, Kharbanda, Manjusha, Gaglani, Suchitra, Rao, Ned, Lewis, Stephanie A, Irving, Emily, Hartmann, Karthik, Natarajan, Alexandra F, Dalton, Ousseny, Zerbo, Malini B, DeSilva, Deepika, Konatham, Edward, Stenehjem, Elizabeth A K, Rowley, Toan C, Ong, Shaun J, Grannis, Chantel, Sloan-Aagard, Jungmi, Han, Jennifer R, Verani, Chandni, Raiyani, Kristin, Dascomb, Sarah E, Reese, Michelle A, Barron, William F, Fadel, Allison L, Naleway, Juan, Nanez, Monica, Dickerson, Kristin, Goddard, Kempapura, Murthy, Nancy, Grisel, Zacharay A, Weber, Brian E, Dixon, Palak, Patel, Bruce, Fireman, Julie, Arndorfer, Nimish R, Valvi, Eric P, Griggs, Carly, Hallowell, Peter J, Embi, Sarah W, Ball, Mark G, Thompson, Mark W, Tenforde, Ruth, Link-Gelles   +45 more
openaire   +2 more sources

Cellular immune response following homologous and heterologous BNT162b2 booster vaccination after primary immunization with BNT162b2 and CoronaVac respectively

Cellular Immunology
Several vaccines targeting SARS-CoV-2 were developed following the COVID-19 outbreak. However, subsequent studies have indicated that humoral immune responses wane over time, particularly with the emergence of new SARS-CoV-2 variants. There is limited understanding of the resilience of T cell-mediated immunity induced by COVID-19 vaccines.
Mat Jusoh, Siti Asmaa, Darren Shaqeel, Sasikaran, Aini Syahida Mat, Yassim, Bushra Solehah Mohd, Rosdan, Amiratul Aifa Mohamad, Asri, Anis Atifah Mohd, Hisham, Rapeah, Suppian, Nur Suhaila, Idris, Rosediani, Muhamad, Maryam, Azlan, Mohd Nor, Norazmi   +10 more
openaire   +2 more sources

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Cell, 2021
Stephanie Longet, David Eyre, Susan Hopkins   +2 more
exaly  

Antibody titres decline 3-month post-vaccination with BNT162b2

Emerging Microbes and Infections, 2021
François Mullier, Grégoire Wieers, Mélanie Closset   +2 more
exaly  

Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults

Clinical Microbiology and Infection, 2022
David Varillas Delgado, Alejo Erice
exaly  

The BNT162b2 mRNA Covid-19 vaccine does not impair sperm parameters

Reproductive BioMedicine Online, 2022
Myriam Safrai, Tal Imbar
exaly  

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine

EBioMedicine, 2023
Daniela Dalla Gasperina, Andreina Baj, Pierpaolo Cavallo   +2 more
exaly